Avenue Therapeutics, Inc.

NasdaqCM:ATXI Stock Report

Market Cap: US$3.4m

Avenue Therapeutics Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

NasdaqCM:ATXI Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
02 Dec 24SellUS$46Neil HerskowitzIndividual23US$2.00
05 Nov 24SellUS$137Jay KranzlerIndividual61US$2.24
30 Sep 24BuyUS$1,250Jay KranzlerIndividual500US$2.50

Insider Trading Volume

Insider Buying: ATXI insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

What is the ownership structure of ATXI?
Owner TypeNumber of SharesOwnership Percentage
Individual Insiders22,5771.18%
Institutions83,5364.37%
Hedge Funds115,0006.02%
Public Companies179,9079.41%
General Public1,510,61379%

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 982.3%.

Top Shareholders

Top 17 shareholders own 20.99% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
9.41%
Fortress Biotech, Inc.
179,907US$318.4k280%no data
6.02%
Armistice Capital LLC
115,000US$203.6k53.3%0.01%
3.3%
Sabby Management, LLC
63,060US$111.6k68.6%1.13%
0.9%
Robert Davidow
17,206US$30.5k0%no data
0.58%
Moss Adams Wealth Advisors LLC
11,000US$19.5k0%no data
0.32%
UBS Asset Management AG
6,143US$10.9k813%no data
0.24%
Lindsay Rosenwald
4,671US$8.3k0%no data
0.091%
Tower Research Capital Europe Limited
1,740US$3.1k-45.7%no data
0.036%
Geode Capital Management, LLC
695US$1.2k0%no data
0.032%
The Vanguard Group, Inc.
617US$1.1k0%no data
0.029%
Wells Fargo & Company, Securities and Brokerage Investments
561US$993.1820%no data
0.029%
Jay Kranzler
559US$989.4-9.84%no data
0.0051%
Neil Herskowitz
97US$171.5-19.2%no data
0.0023%
Curtis Oltmans
44US$77.80%no data
0.00052%
Bank of America Corporation, Asset Management Arm
10US$17.642.9%no data
0.00042%
EMFO, LLC
8US$14.20%no data
0.00005%
JPMorgan Chase & Co, Brokerage and Securities Investments
1US$1.70%no data

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/22 20:30
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Avenue Therapeutics, Inc. is covered by 4 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jonathan AschoffB. Riley Wealth
Antonio ArceH.C. Wainwright & Co.
Jason McCarthyMaxim Group